Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;34(7):e13171.
doi: 10.1111/jne.13171. Epub 2022 Jun 22.

Nuclear hormone receptors in demyelinating diseases

Affiliations
Review

Nuclear hormone receptors in demyelinating diseases

Rocío I Zorrilla Veloz et al. J Neuroendocrinol. 2022 Jul.

Abstract

Demyelination results from the pathological loss of myelin and is a hallmark of many neurodegenerative diseases. Despite the prevalence of demyelinating diseases, there are no disease modifying therapies that prevent the loss of myelin or promote remyelination. This review aims to summarize studies in the field that highlight the importance of nuclear hormone receptors in the promotion and maintenance of myelination and the relevance of nuclear hormone receptors as potential therapeutic targets for demyelinating diseases. These nuclear hormone receptors include the estrogen receptor, progesterone receptor, androgen receptor, vitamin D receptor, thyroid hormone receptor, peroxisome proliferator-activated receptor, liver X receptor, and retinoid X receptor. Pre-clinical studies in well-established animal models of demyelination have shown a prominent role of these nuclear hormone receptors in myelination through their promotion of oligodendrocyte maturation and development. The activation of the nuclear hormone receptors by their ligands also promotes the synthesis of myelin proteins and lipids in mouse models of demyelination. There are limited clinical studies that focus on how the activation of these nuclear hormone receptors could alleviate demyelination in patients with diseases such as multiple sclerosis (MS). However, the completed clinical trials have reported improved clinical outcome in MS patients treated with the ligands of some of these nuclear hormone receptors. Together, the positive results from both clinical and pre-clinical studies point to nuclear hormone receptors as promising therapeutic targets to counter demyelination.

Keywords: demyelination; hormone receptors; myelin; nuclear receptors; steroid hormones.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Overview of the role of nuclear hormone receptors in regulating myelination. The activation of nuclear hormone receptors by their respective ligands results in the transcription of genes involved in lipid metabolism, proliferation and differentiation of oligodendrocyte precursor cells and maintenance of myelination.

References

    1. Mangelsdorf DJ, et al., The nuclear receptor superfamily: the second decade. Cell, 1995. 83(6): p. 835–9. - PMC - PubMed
    1. Sever R and Glass CK, Signaling by nuclear receptors. Cold Spring Harb Perspect Biol, 2013. 5(3): p. a016709. - PMC - PubMed
    1. Fuentes N and Silveyra P, Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol, 2019. 116: p. 135–170. - PMC - PubMed
    1. Jensen EV, et al., Estrogen-binding substances of target tissues. Science, 1967. 158(3800): p. 529–30. - PubMed
    1. Jensen EV, et al., A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A, 1968. 59(2): p. 632–8. - PMC - PubMed

Publication types

Substances